Exposure-response analysis of tigecycline in pharmacodynamic simulations using different size inocula of target bacteria

International Journal of Antimicrobial Agents

Volumn 36, Issue 2, 2010, Pages 137-144

  Sevillano, D ^a   Aguilar, L ^a   Alou, L ^a   Gimenez M J ^a   Gonzalez N ^a   Torrico, M ^a   Cafini, F ^a   Garcia Rey, C ^b   Garcia Escribano, N ^b   Prieto, J ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

Enterococcus faecium; Glycylcyclines; Inoculum effect; Pharmacodynamics; Staphylococcus aureus

Indexed keywords

EXTENDED SPECTRUM BETA LACTAMASE; TIGECYCLINE;

AREA UNDER THE CURVE; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG RESPONSE; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; SIMULATION; STAPHYLOCOCCUS AUREUS; VANCOMYCIN RESISTANT STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; COMPUTER SIMULATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENTEROCOCCUS FAECIUM; ESCHERICHIA COLI; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; STEM CELLS;

EID: 77953811351     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2010.03.021     Document Type: Article

References (39)

1. Ku Y.H., Chuang Y.C., Yu W.L. In vitro activity of tigecycline against clinical isolates of extended-spectrum β-lactamase-producing Klebsiella pneumoniae, Serratia marcescens and Enterobacter cloacae. J Microbiol Immunol Infect 2008, 41:332-336.
2. Woodford N., Zhang J., Warner M., Kaufmann M.E., Matos J., Macdonald A., et al. Arrival of Klebsiella pneumoniae producing KPC carbapenemase in the United Kingdom. J Antimicrob Chemother 2008, 62:1261-1264.
3. Jones R.N. Microbiological features of vancomycin in the 21st century: minimum inhibitory concentration creep, bactericidal/static activity, and applied breakpoints to predict clinical outcomes or detect resistant strains. Clin Infect Dis 2006, 42(Suppl. 1):S13-S14.
4. Tenover F.C., Moellering R.C. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis 2007, 44:1208-1215.
5. Lentino J.R., Narita M., Yu V.L. New antimicrobial agents as therapy for resistant Gram-positive cocci. Eur J Clin Microbiol Infect Dis 2008, 27:3-15.
6. Saribas S., Bagdatli Y. Vancomycin tolerance in enterococci. Chemotherapy 2004, 50:250-254.
7. Sorlózano A., Gutiérrez J., Salmerón A., Luna J.D., Martínez-Checa F., Román J., et al. Activity of tigecycline against clinical isolates of Staphylococcus aureus and extended-spectrum β-lactamase-producing Escherichia coli in Granada, Spain. Int J Antimicrob Agents 2006, 28:532-536.
8. Conejo M, Hernàndez J, Pascual A. Comparative activity of tigecycline, cefepime and imipenem against clinical isolates of Klebsiella pneumoniae producing extended spectrum β-lactamases, plasmid-mediated AmpC-type β-lactamases or both, associated or not with porin deficiency. Clin Microbiol Infect 2007;13(Suppl. 1)/Int J Antimicrob Agents 2007;29(Suppl. 2):S199. In: Abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)/25th International Congress of Chemotherapy (ICC) Congress, Munich, Germany; 31 March-3 April 2007 [Abstract no. 1733_290].
9. Florescu I., Beuran M., Dimov R., Razbadauskas A., Bochan M., Fichev G., et al. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother 2008, 62(Suppl. 1):i17-i28.
10. Moellering R.C. Enterococcus species, Streptococcus bovis, and Leuconostoc species. Mandell, Douglas, and Bennett principles and practice of infectious diseases 2005, 2411-2421. Elsevier Churchill Livingstone, Philadelphia, PA. 6th ed. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
11. Falagas M.E., Karageorgopoulos D.E., Dimopoulos G. Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of tigecycline. Curr Drug Metab 2009, 10:13-21.
12. Walsh T.R., Bolmstrom A., Qwarnstrom A., Ho P., Wootton M., Howe R.A., et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001, 39:2439-2444.
13. Rodríguez-Baño J., Navarro M.D., Romero L., Martínez-Martínez L., Muniain M.A., Perea E.J., et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004, 42:1089-1094.
14. Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that growth aerobically; approved standard. 7th ed. Document M7-A7. Wayne, PA: CLSI; 2006.
15. National Committee for Clinical Laboratory Standards. Methods for determining bactericidal activity of antimicrobial agents; approved guideline. Document M26-A. Wayne, PA: NCCLS; 1999.
16. González N., Aguilar L., Alou L., Giménez M.J., Sevillano D., Torrico M., et al. Influence of different resistance traits on the competitive growth of Haemophilus influenzae in antibiotic-free medium and selection of resistant populations by different β-lactams: an in vitro pharmacodynamic approach. J Antimicrob Chemother 2009, 63:1215-1222.
17. Van Wart S.A., Cirincione B.B., Ludwig E.A., Meagher A.K., Korth-Bradley J.M., Owen J.S. Population pharmacokinetics of tigecycline in healthy volunteers. J Clin Pharmacol 2007, 47:727-737.
18. Andrews J.M. Microbiological assays. Clinical antimicrobial assays 1999, 35-44. Oxford University Press, Oxford, UK. 1st ed. D.S. Reeves, R. Wise, J.M. Andrews, L.O. White (Eds.).
19. Firsov A.A., Saverino D., Ruble M., Gilbert D., Manzano B., Medeiros A.A., et al. Predictors of effect of ampicillin-sulbactam against TEM-1 β-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC. Antimicrob Agents Chemother 1996, 40:734-738.
20. White R., Friedrich L., Burgess D., Warkentin D., Bosso J. Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996, 40:904-908.
21. Munford R.S. Sepsis, severe sepsis, and septic shock. Mandell, Douglas, and Bennett principles and practice of infectious diseases 2005, 906-926. Elsevier Churchill Livingstone, Philadelphia, PA. 6th ed. G.L. Mandell, J.E. Bennett, R. Dolin (Eds.).
22. Renaud B., Brun-Buisson C. Outcomes of primary and catheter-related bacteremia. A cohort and case-control study in critically ill patients. Am J Respir Crit Care Med 2001, 163:1584-1590. ICU-Bacteremia Study Group.
23. Brun-Buisson C., Doyon F., Carlet J. Bacteremia and severe sepsis in adults: a multicenter prospective survey in ICUs and wards of 24 hospitals. French Bacteremia-Sepsis Study Group. Am J Respir Crit Care Med 1996, 154:617-624.
24. Rangel-Frausto M.S., Pittet D., Costigan M., Hwang T., Davis C.S., Wenzel R.P. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995, 273:117-123.
25. Brun-Buisson C., Doyon F., Carlet J., Dellamonica P., Gouin F., Lepoutre A., et al. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. JAMA 1995, 274:968-974.
26. Doan T.L., Fung H.B., Mehta D., Riska P.F. Tigecycline: a glycylcycline antimicrobial agent. Clin Ther 2006, 28:1079-1106.
27. Muralidharan G., Micalizzi M., Speth J., Raible D., Troy S. Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects. Antimicrob Agents Chemother 2005, 49:220-229.
28. Kresken M., Leitner E., Seifert H., Peters G., von Eiff C. Susceptibility of clinical isolates of frequently encountered bacterial species to tigecycline one year after the introduction of this new class of antibiotics: results of the second multicentre surveillance trial in Germany (G-TEST II, 2007). Eur J Clin Microbiol Infect Dis 2009, 28:1007-1011.
29. Nørskov-Lauritsen N., Marchandin H., Dowzicky M.J. Antimicrobial susceptibility of tigecycline and comparators against bacterial isolates collected as part of the TEST study in Europe (2004-2007). Int J Antimicrob Agents 2009, 34:121-130.
30. US Food and Drug Administration. TYGACIL® prescribing information. [accessed 9 April 2010]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021821s013s017s018lbl.pdf.
31. British Society for Antimicrobial Chemotherapy. BSAC methods for antimicrobial susceptibility testing. Version 9 January 2010. [accessed 15 April 2010]. http://www.bsac.org.uk/_db/_documents/Version_9_January_2010_final.pdf.
32. Meagher A.K., Ambrose P.G., Grasela T.H., Ellis-Grosse E.J. Pharmacokinetic/pharmacodynamic profile for tigecycline-a new glycylcycline antimicrobial agent. Diagn Microbiol Infect Dis 2005, 52:165-171.
33. Nicasio A.M., Crandon J.L., Nicolau D.P. In vivo pharmacodynamic profile of tigecycline against phenotypically diverse Escherichia coli and Klebsiella pneumoniae. Antimicrob Agents Chemother 2009, 53:2756-2761.
34. Meagher A.K., Passarell J.A., Cirincione B.B., Van Wart S.A., Liolios K., Babinchak T., et al. Exposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections. Antimicrob Agents Chemother 2007, 51:1939-1945.
35. MacGowan A.P. Tigecycline pharmacokinetic/pharmacodynamic update. J Antimicrob Chemother 2008, 62(Suppl. 1):i11-i16.
36. Passarell J.A., Meagher A.K., Liolios K., Cirincione B.B., Van Wart S.A., Babinchak T., et al. Exposure-response analyses of tigecycline efficacy in patients with complicated intra-abdominal infections. Antimicrob Agents Chemother 2008, 52:204-210.
37. Alou L., Giménez M.J., Cafini F., Aguilar L., Sevillano D., González N., et al. In vitro effect of the presence of human albumin physiological concentrations on tigecycline antibacterial activity against Gram-positive and Gram-negative bacteria. J Antimicrob Chemother 2009, 64:1230-1233.
38. Zhang Y.Y., Zhou L., Zhu D.M., Wu P.C., Hu F.P., Wu W.H., et al. In vitro activities of tigecycline against clinical isolates from Shanghai, China. Diagn Microbiol Infect Dis 2004, 50:267-281.
39. Rodvold K.A., Gotfried M.H., Cwik M., Korth-Bradley J.M., Dukart G., Ellis-Grosse E.J. Serum, tissue and body fluid concentrations of tigecycline after a single 100mg dose. J Antimicrob Chemother 2006, 58:1221-1229.